Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib

J Thorac Oncol. 2019 Dec;14(12):e274-e275. doi: 10.1016/j.jtho.2019.07.018.

Authors

Wenfeng Fang¹, Jiadi Gan¹, Yihua Huang¹, Huaqiang Zhou¹, Li Zhang²

Affiliations

¹ Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
² Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address: zhangli@sysucc.org.cn.

PMID: 31757379
DOI: 10.1016/j.jtho.2019.07.018

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Acrylamides / administration & dosage
Acrylamides / pharmacology*
Afatinib / therapeutic use*
Aniline Compounds / administration & dosage
Aniline Compounds / pharmacology*
Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / genetics*
Drug Resistance, Neoplasm
ErbB Receptors / genetics
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics*
Male
Middle Aged
Mutation

Substances

Acrylamides
Aniline Compounds
Antineoplastic Agents
osimertinib
Afatinib
EGFR protein, human
ErbB Receptors